AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
GT Biopharma shares surge 30.09% intraday as Phase 1 trial advances and GTB-5550 IND submission looms.
ByAinvest
Friday, Nov 14, 2025 3:19 pm ET1min read
GT Biopharma surged 30.09% intraday following the release of its Q3 2025 financial results and corporate update. The company highlighted progress in its Phase 1 trial of GTB-3650 for hematologic malignancies, which advanced to Cohort 4 at 10 µg/kg/day, with the next update expected in Q1 2026. It also announced plans to submit an IND application for GTB-5550 targeting B7H3-expressing solid tumors by late December 2025 or January 2026. Reduced R&D expenses ($0.6M vs. $1.3M in Q3 2024) and a $2.6M cash balance sufficient to fund operations into early 2026 were cited as operational improvements. Management emphasized GTB-3650’s safety profile and potential competitive advantages in immuno-oncology, fueling investor optimism about near-term clinical and regulatory milestones.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet